Spero Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
675 Massachusetts Ave Ste 14, Cambridge,...Phone Number
(857) 242-1600Website
www.sperotherapeutics.comRevenue
$61.2 MillionStock Symbol
SPROIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Spero Therapeutics
Spero Therapeutics provides therapies for treating highly resistant bacterial infections. Its headquarters is located in Cambridge, Massachusetts.Explore more
Spero Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spero Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Spero Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Spero Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Spero Therapeutics recently announced quarterly report
Check out if Spero Therapeutics is spiking on competitors!
Spero Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Spero Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Spero Therapeutics has new funding data
Check if Spero Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Spero Therapeutics
Find more new buyers
Compare Similar Companies to Spero Therapeutics
Compare insights from companies similar to Spero Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Spero Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Spero Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Spero Therapeutics.
Spero Therapeutics financials insights
Gather financial insights about Spero Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$33M
2016
Series B
$30M
2017
Series C
$51.7M
Grant
$6.8M
2018
Grant
$54.2M
2019
Grant
$5.9M
2021
Debt
$125M
Spero Therapeutics Tech Stack
Most Recent Scoops
Partnership
Project
Partnership, Product Management, Business Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Person-Based
Partnership
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Product Launch, Pharmaceuticals
Spero Therapeutics News & Media
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that announced that it will report its financial results for the second quarter ended June 30, 2026 on Wednesday, August 12, 2026, after market close. Management will host a conference call and live audio webcast beginning at 5:00 pm EDT to discuss the results and provSpero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer. Dr. Zack will lead Spero’s clinical development strategy and organization as the Company advances its immunology program.Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of KKR (HCRx). Under the agreement, HCRx will receive a portion of future milestone and royalty payments associated with sales of Utebzi™ (tebipenemSpero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
CAMBRIDGE, Mass. and SAN FRANCISCO and SUZHOU, China, July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and Innovent Biologics, Inc. (01801.HK) today announced an exclusive license agreement for SP001 (Innovent R&D code: IBI355), a third-generation Fc-silent anti-CD40L antibody. Spero will receive exclusive rights to develop, research, manufacture, and commercialize SP001 worldwide, excluding Greater China, where Innovent retains rights. Spero currently expects to advance
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Spero Therapeutics
Sign Up For FreeTo access detailed company insights
Spero Therapeutics provides therapies for treating highly resistant bacterial infections. Its headquarters is located in Cambridge, Massachusetts.... Read More
